Skip to main content

Published

Tolerability and pharmacokinetics of leritrelvir in Chinese participants with severe renal impairment and healthy matched control subjects.
Zhou ZY. British Journal of Clinical Pharmacology 2026;92(6):1886-1893.
[The study's aim is to evaluate the pharmacokinetics (PK) and safety of leritrelvir, a novel 3-chymotrypsin-like cysteine protease (3CLpro) inhibitor, in patients with severe renal impairment (RI; n = 7) compared to healthy controls (n = 8).]
Available with an NHS OpenAthens password for eligible users

More details
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Kidney Diseases
Settings
Hospital Settings (Acute)
Population Health
Staff Groups
Pharmacist